Most trials showed improvement in symptoms associated with cannabinoids but these associations did not reach statistical significance in all trials .
There was an increased risk of short-term AEs with cannabinoids , including serious AEs .
Common AEs included dizziness , dry mouth , nausea , fatigue , somnolence , euphoria , vomiting , disorientation , drowsiness , confusion , loss of balance , and hallucination .
CONCLUSIONS AND RELEVANCE There was moderate- quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity .
There was low- quality evidence suggesting that cannabinoids were associated with improvements in nausea and vomiting due to chemotherapy , weight gain in HIV infection , sleep disorders , and Tourette syndrome .
Cannabinoids were associated with an increased risk of short-term AEs
IMPORTANCE Cannabis and cannabinoid drugs are widely used to treat disease or alleviate symptoms , but their efficacy for specific indications is not clear .
OBJECTIVE To conduct a systematic review of the benefits and adverse events ( AEs ) of cannabinoids .
Effect of Sublingual Application of Cannabinoids on Intraocular Pressure: A Pilot Study
Purpose The purpose of this study was to assess the effect on intraocular pressure ( IOP ) and the safety and tolerability of oromucosal administration of a low dose of delta-9-tetrahydrocannabinol ( Δ-9-THC ) and cannabidiol ( CBD ) . Patients and Methods A r and omized , double-masked , placebo-controlled , 4 way crossover study was conducted at a single center , using cannabis-based medicinal extract of Δ-9-THC and CBD .  Six patients with ocular hypertension or early primary open angle glaucoma received a single sublingual dose at 8 AM of 5 mg Δ-9-THC , 20 mg CBD , 40 mg CBD , or placebo . Main outcome measure was IOP . Secondary outcomes included visual acuity , vital signs , and psychotropic effects . Results Two hours after sublingual administration of 5 mg Δ-9-THC , the IOP was significantly lower than after placebo ( 23.5 mm Hg vs. 27.3 mm Hg , P=0.026 ) . The IOP returned to baseline level after the 4-hour IOP measurement . CBD administration did not reduce the IOP at any time . However , the higher dose of CBD ( 40 mg ) produced a transient elevation of IOP at 4 hours after administration , from 23.2 to 25.9 mm Hg ( P=0.028 ) . Vital signs and visual acuity were not significantly changed . One patient experienced a transient and mild paniclike reaction after Δ-9-THC administration . Conclusions A single 5 mg sublingual dose of Δ-9-THC reduced the IOP temporarily and was well tolerated by most patients . Sublingual administration of 20 mg CBD  did not reduce IOP , whereas 40 mg CBD produced a transient increase IOP rise
Most trials showed improvement in symptoms associated with cannabinoids but these associations did not reach statistical significance in all trials .
There was an increased risk of short-term AEs with cannabinoids , including serious AEs .
Common AEs included dizziness , dry mouth , nausea , fatigue , somnolence , euphoria , vomiting , disorientation , drowsiness , confusion , loss of balance , and hallucination .
CONCLUSIONS AND RELEVANCE There was moderate- quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity .
There was low- quality evidence suggesting that cannabinoids were associated with improvements in nausea and vomiting due to chemotherapy , weight gain in HIV infection , sleep disorders , and Tourette syndrome .
Cannabinoids were associated with an increased risk of short-term AEs
IMPORTANCE Cannabis and cannabinoid drugs are widely used to treat disease or alleviate symptoms , but their efficacy for specific indications is not clear .
OBJECTIVE To conduct a systematic review of the benefits and adverse events ( AEs ) of cannabinoids .